Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
respiratory syncytial virus mRNA vaccine (Walvax Biotechnology)
- Development stage
- Unknown
- Lead developer
- Walvax Biotechnology
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The respiratory syncytial virus (RSV) mRNA vaccine is a prophylactic vaccine candidate being developed by Walvax Biotechnology for the prevention of RSV infection. Utilizing messenger RNA technology, the vaccine encodes RSV-specific antigens intended to elicit a protective immune response, including the production of neutralizing antibodies and T-cell activation. The candidate leverages Walvax's established mRNA platform capabilities, which were refined during the company's SARS-CoV-2 vaccine programs (such as AWcorna). As of early 2024, the vaccine is in Phase 1 clinical trials to evaluate its safety, tolerability, and immunogenicity profile in human subjects.
- Other names
- RSV mRNA vaccine
02
Targets
RSV G (Respiratory syncytial virus attachment glycoprotein)
Beyond the preview
Go deeper on respiratory syncytial virus mRNA vaccine (Walvax Biotechnology).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on respiratory syncytial virus mRNA vaccine (Walvax Biotechnology).